Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15878904 | 1.00 | CYP2D6 (0.39) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL450130 | 1.00 | CYP2D6 (0.39) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL17823577 | 0.81 | ALDH1A1 (0.37) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL3632337 | 0.81 | ALDH1A1 (0.37) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL17832663 | 0.81 | ALDH1A1 (0.37) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL9701624 | 0.81 | GAA (0.43) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL1776287 | 0.80 | CRBN (0.40) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL31309789 | 0.77 | IRAK4 (0.36) | IRAK4KMT2A | |
| SCHEMBL6414324 | 0.77 | LMNA (0.38) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL3214114 | 0.76 | LMNA (0.37) | IRAK4MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117402085-A | Novel method for synthesizing D-N-BOC-biphenylpropylamine | 迪嘉药业集团股份有限公司 | 2024-01-16 | — | — | CN | claimed |
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| EP-4380919-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| CN-117402085-A | Novel method for synthesizing D-N-BOC-biphenylpropylamine | 迪嘉药业集团股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117402085-A | Novel method for synthesizing D-N-BOC-biphenylpropylamine | 迪嘉药业集团股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023015164-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022165529-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-2776435-B1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| EP-2146980-A2 | HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma S.A. (BE) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008128919-A2 | HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA S.A. (BE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128919-A2 | HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA S.A. (BE) | 2008-10-30 | — | — | WO | disclosed |
| US-6441189-B1 | WHICH REDUCES RACEMIZATION; (4R)-4-(HYDROXYMETHYL)-1,3-OXAZOLIDIN-2-ONE BY REDUCTION AND BASIFICATION OF THE CORRESPONDING 4-PROTECTED CARBOXY ESTER | ABBOTT LABORATORIES | 2002-08-27 | — | — | US | disclosed |
| US-20020052511-A1 | Process for the preparation of matrix metalloproteinase inhibitors | BAILEY ANNE E (US) | 2002-05-02 | — | — | US | disclosed |
| US-20020019539-A1 | Process for the preparation of matrix metalloproteinase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| WO-2001074792-A2 | PROCESS FOR THE PREPARATION OF MATRIX METALLOPROTEINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-11 | — | — | WO | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | CYP2D6 4759/4885CYP3A4 4777/4885TSHR 4262/4885 |
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | BCL6, BCL6B, BCOR | CYP2D6 969/4885CYP3A4 1903/4885TSHR 3353/4885 |
| US-20020052511-A1 | Process for the preparation of matrix metalloproteinase inhibitors | MMP9, TIMP3, MMP2 | CYP2D6 2351/4885CYP3A4 1764/4885TSHR 3277/4885 |
| US-20020019539-A1 | Process for the preparation of matrix metalloproteinase inhibitors | MMP9, TIMP3, MMP2 | CYP2D6 2351/4885CYP3A4 1764/4885TSHR 3277/4885 |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | CYP2D6 2053/4885CYP3A4 2935/4885TSHR 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.